

Review Article

Mechanism of *Trypanosoma cruzi* Placenta Invasion and Infection: The Use of Human Chorionic Villi Explants

Ricardo E. Fretes^{1,2} and Ulrike Kemmerling³

¹ Department of Histology and Embryology, Faculty of Medicine, Universidad Nacional Córdoba, 5000 Cordoba, Argentina

² IICSHUM and Cathedra of Histology, Embryology and Genetic, Health Department, Universidad Nacional La Rioja, 5300 La Rioja, Argentina

³ Program of Anatomy and Developmental Biology, Institute for Biomedical Sciences, Faculty of Medicine, University of Chile, 8380453 Santiago, Chile

Correspondence should be addressed to Ricardo E. Fretes, rfretes@cme.fcm.unc.edu and Ulrike Kemmerling, ukemmerling@med.uchile.cl

Received 28 November 2011; Revised 6 February 2012; Accepted 14 February 2012

Academic Editor: Demba Sarr

Copyright © 2012 R. E. Fretes and U. Kemmerling. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Congenital Chagas disease, a neglected tropical disease, endemic in Latin America, is associated with premature labor and miscarriage. During vertical transmission the parasite *Trypanosoma cruzi* (*T. cruzi*) crosses the placental barrier. However, the exact mechanism of the placental infection remains unclear. We review the congenital transmission of *T. cruzi*, particularly the role of possible local placental factors that contribute to the vertical transmission of the parasite. Additionally, we analyze the different methods available for studying the congenital transmission of the parasite. In that context, the *ex vivo* infection with *T. cruzi* trypanastigotes of human placental chorionic villi constitutes an excellent tool for studying parasite infection strategies as well as possible local antiparasitic mechanisms.

1. Introduction

Chagas disease was first described by the Brazilian physician, Carlos Chagas, in 1909. He identified the causal agent, the protozoan *Trypanosoma cruzi* (*T. cruzi*), the vectorial transmission and insect reservoirs as well as the clinical signs and symptoms. In other words, he described the complete cycle of the disease and suggested the possibility of congenital transmission [1].

In the human villous hemochorial placenta, fetal and maternal tissues are separated by a fetal epithelium (the trophoblast). Within the villous placenta, a single multinucleated cell layer (syncytiotrophoblast) contacts maternal blood within the intervillous space. Beneath the syncytiotrophoblast reside replicating progenitors (cytotrophoblast) that are separated by a basal lamina from the connective tissue of villous stroma containing vascular endothelium, fibroblasts, and macrophages. The syncytiotrophoblast forms a surface of about 12 m^2 that contacts maternal

blood. Therefore, in case of women with Chagas disease, the parasite has the opportunity to interact with a large cellular surface.

The mechanism of *T. cruzi* congenital transmission can be studied in different ways. One of the possible ways is through the dual placental perfusion system. The dual perfusion that simulates the maternal and fetal circulation could be an excellent method to study the mechanism of the transmission of the parasite [2]. However, this method requires complex equipment and very experienced users. Another possibility is the *ex vivo* infection of human chorionic villi explants, in which samples of placental tissue (chorionic villi) can be challenged *in vitro* with *T. cruzi* or other pathogens. This system is preferred to analyze the process of infection of the placental barrier, although the immune system does not participate. The analysis of infection in animal models is not treated in this paper because their placentas are not similar to human placenta. Also, pathological findings of placentas are not deeply described because they represent the final

stage of the placental infection process, and so, it is hard to understand an ongoing process.

The aim of the present paper is to review the congenital transmission of *T. cruzi*, particularly the role of possible local placental factors which contribute to the vertical transmission of the parasite and can be studied in the *ex vivo* infection model of human chorionic villi explants.

2. Chagas Disease

Chagas disease develops in three phases. The acute phase is first developed, immediately after infection, with high levels of parasitemia and symptoms in only some patients (regional lymph node enlargement, bipalpebral unilateral edema, or Romaña's sign, and characteristic electrocardiogram alterations). In most cases, acute infection is not accompanied by clinical findings, thus moving onto the latent phase that can last for months or years. The chronic phase, present in 30% of infected individuals, is associated with mega colon, mega esophagus, degeneration of the autonomous nervous system, arrhythmias, and abnormal growth of the heart with progressive insufficiency, with evident negative impact on the patient's health. In this phase the disease can be handicapping, and can either be the concurrent or the direct cause of death. The course of the disease depends on diverse factors: parasite load at the site of inoculation, both the parasite's genetic group and strain, whether it is an infection *de novo* or reinfection, the host's immunologic status, and the type of vector (triatomid) [3, 4].

3. Congenital Chagas Disease

Congenital *T. cruzi* infection is associated with premature labor, low birth weight, and stillbirths [5–7]. Serologic prevalence among pregnant women may reach 80%, and rates of congenital infection vary from 1–21% [8–11]. In Argentina the transmission rate is estimated between 2–12% [12]. In Chile, in two of the endemic regions (IV and V regions), the congenital transmission rate of the parasite is 8.4% [13]. According to WHO/PAHO the number of infected women at fertile age is approximately 1.8 million and it is estimated that 14,400 neonates are being infected each year [14], this is another reason why this form of transmission becomes epidemiologically more important. Additionally, congenital transmission is partly responsible for the "globalization of Chagas's disease" [10, 15].

Congenital Chagas transmission implies a *T. cruzi* seropositive mother and a postpartum detection of parasites in the newborn. Congenital Chagas disease is diagnosed by direct microscopic examination of blood samples, PCR, or standard serological assays. The latter can be carried out in infants when IgG antibodies transferred from the mother have been eliminated (8–9 months after birth).

During congenital transmission, the parasite reaches the fetus by crossing the placental barrier [16–22]. The fact that only a percentage of the infected mothers transmit parasites to their fetuses raises the question of the ability of the placenta as well as the immunological status of mother and fetus/newborn to impair the parasite transmission.

Therefore, it is thought that congenital Chagas disease is the product of a complex interaction between the parasite, the maternal and fetus/newborn immune responses, and placental factors [9, 18].

4. The Parasite

T. cruzi is a haemoflagellated protozoan of the Kinetoplastida order and Trypanosomatidae family [22]. The parasite's biological cycle includes three cellular forms characterized by the relative positions of the flagellum, kinetoplast, and nucleus [23]: (1) trypomastigotes: approximately 20 µm in length and sub terminal kinetoplast. They constitute the nonreplicative, mammalian infecting cellular form that is found in the blood and in the posterior intestine of triatomids. In mammals, this is the cellular form that disseminates infection through blood. (2) Epimastigotes: also 20 µm in length with a kinetoplast anterior to the nucleus. They represent the multiplying parasite form in the triatomid intestine. (3) Amastigotes: approximately 2 µm in diameter, rounded, with no emergent flagellum. It multiplies within the mammalian host cells, forming nests, until they rupture after several cell divisions. Before their release from the host cells, amastigotes differentiate into trypomastigotes which once released, invade the blood stream; they may then enter any other nucleated cell. Epimastigotes can be grown in axenic cultures while amastigotes are grown in cultured mammalian cells, releasing trypomastigotes that can be harvested to perform *in vitro* assays.

T. cruzi displays great biological, biochemical, and genetic diversity; therefore different strains of the parasite have been identified and classified into six discrete typing units (DTUs) [24, 25]. Strains of *T. cruzi* have been involved in different clinical forms of Chagas disease [26, 27], thus implicating a different genetic population in tissue tropism, replication, and virulence, and in consequence in disease outcome. *T. cruzi* strains corresponding to different DTUs might have relevant consequences on congenital transmission and fetal/neonatal pathology, even though Virreira et al. [28] and Burgos et al. [9] concluded that congenital transmission of *T. cruzi* is not associated with genetic polymorphism of *T. cruzi*. However, Solana et al. [29] and Triquell et al. [21] described biological differences among subpopulations of *T. cruzi* in experimental vertical transmission and placental infection.

5. Mother and Fetus/Newborn Immune Response

The immune system is fundamental to protect the mother against the environment, and to prevent damage to the fetus. During pregnancy the maternal immune system is characterized by a reinforced network of cellular and molecular recognition, communication, trafficking and repair; it raises the alarm to maintain the wellbeing of the mother and the fetus. On the other hand, the fetus provides a developing active immune system that will modify the way the mother responds to the environment, providing a uniqueness of the immune system responses during pregnancy [30].

A crucial factor to stop, limit, or permit the development of fetal/neonatal infection relates to the capacity of the mother and fetus/newborn to mount innate and/or specific immune response(s) against pathogens. Clinical studies have shown a strong association between intrauterine infections and pregnancy disorders such as abortion, preterm labor, intrauterine growth retardation, and preeclampsia [31]. As described above, congenital *T. cruzi* infection is associated with some of these pathologies [5–7, 15]. Production of proinflammatory cytokines can be observed in uninfected newborn from infected mothers [15]. Contrarily, the levels of inflammation markers and activation of NK cells are rather low in congenitally infected newborns [32]. This data highly suggests a protective role of such innate defenses in an uninfected newborn from infected mothers. On the other hand, maternal *T. cruzi*-specific IgG antibodies play protective roles in mothers and in fetuses when antibodies are transferred through the placenta [33] and also may contribute to a reduction in parasitaemia [15].

6. Placenta

The placenta is the principal site for the exchange of nutrients and gases between the mother and fetus. This organ plays an important role in hormone, peptide, and steroid synthesis necessary for a successful pregnancy [34]. The human placenta is classified as a hemochorial villous placenta in which the free chorionic villi, formed by the trophoblast and the villous stroma, are the functional units. The trophoblast contacts maternal blood in the intervillous space, and it is separated by a basal lamina from the villous stroma, which is connective tissue containing the vascular endothelium, fibroblasts, and macrophages (Figure 1) [35]. Trophoblast, basal lamina, and villous stroma with the endothelium of fetal capillaries form the placental barrier that must be crossed by different pathogens, including *T. cruzi*, to infect the fetus during vertical transmission [16–22, 36–41].

Placentas from mother with acute Chagas disease (high parasitaemia) show severe histopathological changes, such as extensive necrosis, inflammatory infiltrate, and amastigote nests [5]. Contrarily, placentas from mother with chronic Chagas disease do not present necrotic foci and inflammatory infiltrate. Although parasite antigens can be visualized in the villous stroma, the typical amastigote nests are not present [22]. In accordance with these results, in *ex vivo* infected placental explants, though parasite antigens and DNA can be detected [17, 18, 42], amastigote nests are not observed. Only few individual parasites can be detected. This evidence suggests that antiparasite mechanisms may exist in the placental tissue of women suffering chronic Chagas disease.

7. Possible Antiparasitic Mechanisms of the Placenta

We updated the importance of the presence of the causal agent of Chagas disease in the intervillous space of human placentas, the viability of the parasite in this environment,




FIGURE 1: Electron micrograph of a chorionic villous human placenta. Picture depicts the intervillous space (1) and the placental barrier formed by the syncytiotrophoblast (2), a discontinuous cytotrophoblast (3), basal laminae (asterix), connective tissue, and fetal vessels (4).

and the process of infection of the placental tissue, mainly by *ex vivo* and *in vitro* studies.

- (1) Clearance of *T. cruzi* from the intervillous space is associated with the risk of congenital transmission. Thus, a high parasitaemia, as in acute infection, correlates with a higher transmission rate [15, 18, 43, 44]. Thus the amount of parasites could be an important risk factor for mother to fetus transmission of *T. cruzi*. There are only few publications analyzing the survival of *T. cruzi* in the placental environment. Triquell et al. [21], employing chorionic villi *ex vivo* and *in vitro* infection model cocultured with trypomastigotes from two different strains of *T. cruzi*, observed that one of the strains presents a better survival rate than the other in the placental environment. Furthermore, the two strains of *T. cruzi* respond differently when they were treated with placental media. Therefore, the great biological, biochemical, and genetic diversity of the parasite may determine, at least partially, the capacity of placental infection. These results open a new concept, that placenta might exert a clearance of the parasite from the intervillous space, and that different populations of *T. cruzi* have different survival capacities in that environment.
- (2) Contact time between *T. cruzi* and the trophoblast in the intervillous space: the time that the parasite remains in the intervillous space in contact with the syncytiotrophoblast is poorly known. Placental barrier is constituted by the trophoblast tissue, that comprises a continuous multinucleated, nonreplicating cell layer, the syncytiotrophoblast, a replicating




FIGURE 2: Estimation of *T. cruzi* contact with the placenta in infected mothers.

layer of cytotrophoblasts that fuses with the STB, a basal lamina, and an underlying villous stroma or connective tissue, that includes vascular endothelium [35]. The placental barrier must be crossed by the parasites, therefore the time that *T. cruzi* trypomastigotes stay in the intervillous space and interact with the syncytiotrophoblast is of outmost importance. Shippey et al. [45] in a dual perfusion system of placental cotyledons observed *T. cruzi* DNA in the maternal effluents at 30 min, 60 min, and 90 min after injection an only one bolus of *T. cruzi* trypomastigotes through the maternal perfusate. There was no parasite DNA in the fetal effluent, indicating there was no passage to fetal circulation despite the great concentration of parasites injected. However, the perfusion time was only 120 min in these experiments. Contrarily, in the *ex vivo* infection of chorionic villi explants, a reproducible infection is obtained after 24 hours of coincubation with the parasite [17]. However, the perfusion experiments indicate that *T. cruzi* is present in the intervillous space at least for an hour and half. Despite this long time of interaction, *T. cruzi* was not able to invade or survive in the placental barrier, indicating a defense mechanism of the placental barrier against the causal parasite of Chagas.

- (3) Placental infection: the *ex vivo* and *in vitro* infection of human chorionic villi explants from human term placenta with the parasite is an excellent and easy way to study the mechanism of cellular and tissue invasion mechanisms. The explants can be kept in culture for several days [46], where constituent cells and tissues are in a more physiological condition than their isolated counterparts in monolayer cell culture models. Another advantage of this model is that the cells retain physical contact with the basal lamina and continue to receive paracrine growth factor signals from the underlying villous stroma.

In our laboratories, we have established the optimal conditions for the *ex vivo* infection of chorionic villi explants with *T. cruzi* [17, 18, 20, 21, 36–41, 47]. The coincubation of 10^5 or 10^6 trypomastigotes produces a reproducible infection of the chorionic villi [17]. This parasite's concentration may seem to be extremely high, but if we consider the amount of blood that circulates through the placenta every day, and then calculate the number of parasites that reaches the placenta, the parasite concentration recommended for *ex vivo* infection is not high. Therefore, if we consider that the cardiac output in women is 4250 mL/min, and that during pregnancy the circulating blood volume increases in 20% and the cardiac output in 40%. Then the cardiac output in pregnant women is 5950 mL/min. From this output, 10% reaches the pregnant uterus and 80% of this volume reaches the placenta. Taking into account all the data, a volume of 475 mL/minute of blood reaches the placenta [48]. Considering a parasitemia as low as 0,1 to 1 parasite/mL, a total of 68544 to 685440 parasites circulate through the placenta in 24 hours (Figure 2). On the other hand, in pregnant women with acute Chagas disease, Torrico et al. [11] have reported parasitemias over 40 parasites/mL; therefore, in this condition a total of 27 million parasites circulate in 24 hours in the placenta. If we consider all these data, our experimental conditions are not far from *in vivo* conditions.

The trophoblast, the first tissue that is in contact with the parasite in the intervillous space, constitutes a potential barrier to *T. cruzi*. We observed that the most notable tissue damage induced by *T. cruzi* in the chorionic villi explants is the trophoblast detachment and destruction. Additionally, the parasite induces selective disorganization of basal lamina, collagen I destruction [17], and apoptosis (especially in the trophoblast) in infected chorionic villi explants [49]. In accordance, we detected similar histopathological changes in

placentas from women with chronic Chagas disease ([22] manuscript in this number of *J. of Tropical Medicine*). Therefore, the similar histopathological changes observed in chagasic mothers and in *ex vivo* infected chorionic villi, validates the latter model. The extracellular matrix alteration produced by *T. cruzi* not only promotes its motility in tissues and its entrance into cells, but also alters the presence of cytokines and chemokines, which in turn permits *T. cruzi* to modulate and evade both the inflammatory and immune responses [16, 50, 51]. Alternatively, these changes in ECM function may be part of a local placental defense mechanism, which could explain why only very few parasites can be detected in the placenta. Similar effects can be observed in the chorionic villi explants during *ex vivo* infection, since placental explants do not allow a sustained infection by *T. cruzi* [19]. Thus, the placenta controls the productive infection of *T. cruzi* in chorionic villous and exerts a protective function to fetus.

In order to understand the mechanism by which *T. cruzi* fuses with trophoblast plasma membrane, Calderón and Fabro [52] studied the interaction between syncytial plasma membranes from the human placenta and from the parasites, founding modifications of membrane lipids and proteins of the syncytiotrophoblast. Additionally, modifications of enzyme activities in the chorionic villi have been described [37–39]. For instance, placental alkaline phosphatase (PLAP) is a glycosylphosphatidylinositol anchored plasma membrane protein present in the trophoblast that decreases its activity in chagasic women and is related to congenital transmission [53]. In *ex vivo* infected chorionic villi, pretreatment of the placental tissue with phospholipase C prevents the parasite-induced decrease of PLAP activity and significantly reduces the infectivity of *T. cruzi*. These results are consistent with a pathogenetic role for placental alkaline phosphatase in congenital Chagas disease [36, 54]. Additionally, *T. cruzi* induces in the *ex vivo* infection model an increase of lysosomal vesicles in the trophoblast, which are fundamental during cell invasion of the parasite [36–39].

Analyzing the process of trophoblast infection by *T. cruzi* in an *in vitro* system culturing monolayer trophoblasts cells in interaction with infective trypomastigotes, it was shown that two types of chorionic villi trophoblasts, syncytiotrophoblast, and cytotrophoblast have a differential susceptibility to infection by the causal agent of congenital Chagas disease [55]. The reduced infection in the syncytiotrophoblast was associated to fewer viable parasites in the culture medium and increased levels of nitric oxide. These results emphasize the importance of the integrity of the first placental barrier, the syncytiotrophoblast, in order to avoid a *T. cruzi* infection of the inner trophoblasts or stromal chorionic villi cells. As it was described above, structural trophoblast alteration is a common sign of miscarriages and premature births in placentas of chagasic women and strongly associated to the congenital transmission of *T. cruzi*. In these clinical situations, the detachment of the first placental barrier is a common sign which is also associated to parasitism of the placental tissue [9]. Thus, differential infection between the first placental barrier with respect to the inner trophoblast or stromal cells could

represent a mechanism of invasion of the human placenta by *T. cruzi*.

8. Conclusion

Congenital Chagas transmission constitutes an increasing public health problem, and it is responsible for the urbanization and spreading of the disease to nonendemic areas of Latin America, United States of America, and Europe [18, 21]. The fact that the *ex vivo* infection of the chorionic villi explants with the parasite reproduces the *in vivo* infection in terms of cellular changes and infectivity makes it an excellent tool for studying parasite infection strategies as well as possible local antiparasitic mechanisms.

Acknowledgments

This work was supported by Secretary of Science and Technology, Universidad Nacional de La Rioja; Ministry of Science and Technology Córdoba-PID 48; Secretary of Science and Technology-Universidad Nacional de Córdoba; PME, Secretary of Science and Technology, National University of Córdoba [3042/09 and 3416/11] (to REF); Grants 11080166, 1120230 from FONDECYT and CONICYT-PBCT Anillo ACT 112, Chile (to UK); and Grant “Programa de Cooperación Científica Internacional” CONICYT/MINCYT 2011-595-CH/11/08 (to REF and UK).

References

- [1] J. Clayton, “Chagas disease 101,” *Nature*, vol. 465, no. 7301, pp. S4–S5, 2010.
- [2] H. Schneider and J. Dancis, “*In vitro* perfusion of human placental tissue,” *Contributions to Gynecology and Obstetrics*, vol. 13, pp. 5–176, 1984.
- [3] F. Kierszenbaum, “Mechanisms of pathogenesis in Chagas disease,” *Acta Parasitologica*, vol. 52, no. 1, pp. 1–12, 2007.
- [4] A. R. L. Teixeira, R. J. Nascimento, and N. R. Sturm, “Evolution and pathology in Chagas disease: a review,” *Memorias do Instituto Oswaldo Cruz*, vol. 101, no. 5, pp. 463–491, 2006.
- [5] A. M. Altemani, A. L. Bittencourt, and A. M. A. Lana, “Immunohistochemical characterization of the inflammatory infiltrate in placental Chagas’ disease: a qualitative and quantitative analysis,” *American Journal of Tropical Medicine and Hygiene*, vol. 62, no. 2, pp. 319–324, 2000.
- [6] A. L. Bittencourt, “Congenital Chagas disease,” *American Journal of Diseases of Children*, vol. 130, no. 1, pp. 97–103, 1976.
- [7] A. L. Bittencourt, “Possible risk factors for vertical transmission of Chagas’ disease,” *Revista do Instituto de Medicina Tropical de São Paulo*, vol. 34, no. 5, pp. 403–408, 1992.
- [8] S. B. Blanco, E. L. Segura, E. N. Cura et al., “Congenital transmission of *Trypanosoma cruzi*: an operational outline for detecting and treating infected infants in northwestern Argentina,” *Tropical Medicine and International Health*, vol. 5, no. 4, pp. 293–301, 2000.
- [9] J. M. Burgos, J. Altcheh, M. Bisio et al., “Direct molecular profiling of minicircle signatures and lineages of *Trypanosoma cruzi* bloodstream populations causing congenital Chagas disease,” *International Journal for Parasitology*, vol. 37, no. 12, pp. 1319–1327, 2007.

- [10] L. V. Kirchhoff, "Chagas disease (American Trypanosomiasis): a tropical disease now emerging in the United States," in *Emerging Infections*, W. M. Scheld, C. William, and J. M. Hughes, Eds., vol. 3, pp. 111–134, ASM Press, Washington, DC, USA, 1999.
- [11] F. Torrico, M. Castro, M. Solano et al., "Effects of maternal infection with *Trypanosoma cruzi* in pregnancy development and in the newborn infant," *Revista da Sociedade Brasileira de Medicina Tropical*, vol. 38, pp. 73–76, 2005.
- [12] R. E. Görtler, E. L. Segura, and J. E. Cohen, "Congenital transmission of *Trypanosoma cruzi* infection in Argentina," *Emerging Infectious Diseases*, vol. 9, no. 1, pp. 29–32, 2003.
- [13] M. I. Jercic, R. Mercado, and R. Villarroel, "Congenital *Trypanosoma cruzi* infection in neonates and infants from two regions of Chile where Chagas' disease is endemic," *Journal of Clinical Microbiology*, vol. 48, no. 10, pp. 3824–3826, 2010.
- [14] World Health Organization, "Estimación cuantitativa de la enfermedad de Chagas en las Américas," Tech. Rep. OPS/HDM/CD/425-06, World Health Organization, Geneva, Switzerland, 2006.
- [15] R. C. Lambert, K. N. Kolivras, L. M. Resler, C. C. Brewster, and S. L. Paulson, "The potential for emergence of chagas disease in the United States," *Geospatial Health*, vol. 2, no. 2, pp. 227–239, 2008.
- [16] Y. Carlier and C. Truyens, "Maternal-fetal transmission of *Trypanosoma cruzi*," in *American Trypanosomiasis Chagas Disease One Hundred years of Research*, J. Telleria and M. Tibayrenc, Eds., pp. 539–581, Elsevier, New York, NY, USA, 2010.
- [17] J. Duaso, G. Rojo, G. Cabrera et al., "*Trypanosoma cruzi* induces tissue disorganization and destruction of chorionic villi in an *ex vivo* infection model of human placenta," *Placenta*, vol. 31, no. 8, pp. 705–711, 2010.
- [18] U. Kemmerling, C. Bosco, and N. Galanti, "Infection and invasion mechanisms of *Trypanosoma cruzi* in the congenital transmission of chagas' disease: a proposal," *Biological Research*, vol. 43, no. 3, pp. 307–316, 2010.
- [19] A. G. Schijman, "Congenital chagas disease," in *Congenital and Other Related Infectious Diseases of the Newborn*, vol. 13, pp. 223–258, Perspectives in Medical Virology, New York, NY, USA, 2006.
- [20] C. D. Luján, M. F. Triquell, A. Sembaj, C. E. Guerrero, and R. E. Fretes, "*Trypanosoma cruzi*: productive infection is not allowed by chorionic villous explant from normal human placenta in vitro," *Experimental Parasitology*, vol. 108, no. 3–4, pp. 176–181, 2004.
- [21] M. F. Triquell, C. Díaz-Luján, H. Freilij, P. Paglini, and R. E. Fretes, "Placental infection by two subpopulations of *Trypanosoma cruzi* is conditioned by differential survival of the parasite in a deleterious placental medium and not by tissue reproduction," *Transactions of the Royal Society of Tropical Medicine and Hygiene*, vol. 103, no. 10, pp. 1011–1018, 2009.
- [22] J. Duaso, E. Yanez, C. Castillo et al., "Reorganization of extracellular matrix in placentas from women with asymptomatic chagas disease: mechanism of parasite invasion or local placental defense?" *Journal of Tropical Medicine*, vol. 2012, Article ID 758357, 8 pages, 2012.
- [23] A. Prata, "Clinical and epidemiological aspects of Chagas disease," *Lancet Infectious Diseases*, vol. 1, no. 2, pp. 92–100, 2001.
- [24] J. Telleria, D. G. Biron, J. P. Brizard et al., "Phylogenetic character mapping of proteomic diversity shows high correlation with subspecific phylogenetic diversity in *Trypanosoma cruzi*," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 47, pp. 20411–20416, 2010.
- [25] B. Zingales, S. G. Andrade, M. R. S. Briones et al., "A new consensus for *Trypanosoma cruzi* intraspecific nomenclature: second revision meeting recommends TcI to TcVI," *Memorias do Instituto Oswaldo Cruz*, vol. 104, no. 7, pp. 1051–1054, 2009.
- [26] W. O. Dutra, M. O. C. Rocha, and M. M. Teixeira, "The clinical immunology of human Chagas disease," *Trends in Parasitology*, vol. 21, no. 12, pp. 581–587, 2005.
- [27] B. Zingales, B. S. Stolf, R. P. Souto, O. Fernandes, and M. R. S. Briones, "Epidemiology, biochemistry and evolution of *Trypanosoma cruzi* lineages based on ribosomal RNA sequences," *Memorias do Instituto Oswaldo Cruz*, vol. 94, no. 1, pp. 159–164, 1999.
- [28] M. Virreira, C. Alonso-Vega, M. Solano et al., "Congenital Chagas disease in Bolivia is not associated with DNA polymorphism of *Trypanosoma cruzi*," *American Journal of Tropical Medicine and Hygiene*, vol. 75, no. 5, pp. 871–879, 2006.
- [29] M. E. Solana, A. M. Celentano, V. Tekiel, M. Jones, and S. M. González Cappa, "*Trypanosoma cruzi*: effect of parasite subpopulation on murine pregnancy outcome," *Journal of Parasitology*, vol. 88, no. 1, pp. 102–106, 2002.
- [30] G. Mor and I. Cardenas, "The immune system in pregnancy: a unique complexity," *American Journal of Reproductive Immunology*, vol. 63, no. 6, pp. 425–433, 2010.
- [31] K. Koga and G. Mor, "Toll-like receptors at the maternal-fetal interface in normal pregnancy and pregnancy disorders," *American Journal of Reproductive Immunology*, vol. 63, no. 6, pp. 587–600, 2010.
- [32] E. Hermann, A. Berthe, C. Truyens et al., "Killer cell immunoglobulin-like receptor expression induction on neonatal CD8+ T cells in vitro and following congenital infection with *Trypanosoma cruzi*," *Immunology*, vol. 129, no. 3, pp. 418–426, 2010.
- [33] S. F. Breniere, M. Bailly, R. Carrasco, and Y. Carlier, "Transmission transplacentaire des anticorps anti-*Trypanosoma cruzi*," *Cahiers ORSTOM. Série Entomologie Médicale et Parasitologie*, vol. 21, no. 3, pp. 139–140, 1983.
- [34] K. L. Moore and T. V. N. Perseaud, *The Developing Human, Clinically Oriented Embryology*, Elsevier, New York, NY, USA, 7th edition, 2004.
- [35] K. Bernische, P. Kaufmann, and R. N. Baergen, *Pathology of the Human Placenta*, Springer, New York, NY, USA, 2006.
- [36] R. E. Fretes and S. P. de Fabro, "*Trypanosoma cruzi*: modification of alkaline phosphatase activity induced by tryptomastigotes in cultured human placental villi," *Revista do Instituto de Medicina Tropical de São Paulo*, vol. 32, no. 6, pp. 403–408, 1990.
- [37] R. E. Fretes and S. P. de Fabro, "Human chagasic placental localization of enzymes associated to syncytiotrophoblast membrane," *Comunicaciones Biológicas*, vol. 9, pp. 51–59, 1990.
- [38] R. E. Fretes and S. P. de Fabro, "Increase of Hofbauer cells in human placentas cocultured *in vitro* with *Trypanosoma cruzi*," *Revista de la Facultad de Ciencias Medicas*, vol. 52, no. 1, pp. 7–12, 1994.
- [39] R. E. Fretes and S. P. de Fabro, "*In vivo* and *in vitro* analysis of lysosomes and acid phosphatase activity in human chagasic placentas," *Experimental and Molecular Pathology*, vol. 63, no. 3, pp. 153–160, 1995.
- [40] L. Mezzano, G. Repossi, R. E. Fretes, S. Lin, M. J. Sartori, and S. P. de Fabro, "*In vitro* infection of *Trypanosoma cruzi* causes decrease in glucose transporter protein-1 (GLUT1) expression

- in explants of human Placental Villi cultured under normal and high glucose concentrations,” *Journal of Tropical Medicine*, vol. 2012, Article ID 969243, 8 pages, 2012.
- [41] L. Mezzano, M. J. Sartori, S. Lin, G. Repossi, and S. P. de Fabro, “Placental alkaline phosphatase (PLAP) study in diabetic human placental villi infected with *Trypanosoma cruzi*,” *Placenta*, vol. 26, no. 1, pp. 85–92, 2005.
 - [42] A. Al-Khan, I. L. Aye, I. Barsoum et al., “IFPA meeting 2010 workshops report II: placental pathology; trophoblast invasion; fetal sex; parasites and the placenta; decidua and embryonic or fetal loss; trophoblast differentiation and syncytialisation,” *Placenta*, vol. 32, supplement 2, pp. S90–S99, 2011.
 - [43] E. Moretti, B. Basso, I. Castro et al., “Chagas’ disease: study of congenital transmission in cases of acute maternal infection,” *Revista da Sociedade Brasileira de Medicina Tropical*, vol. 38, no. 1, pp. 53–55, 2005.
 - [44] H. Freilij and J. Altcheh, “Congenital Chagas’ disease: diagnostic and clinical aspects,” *Clinical Infectious Diseases*, vol. 21, no. 3, pp. 551–555, 1995.
 - [45] S. H. Shippey, C. M. Zahn, M. M. Cisar, T. J. Wu, and A. J. Satin, “Use of the placental perfusion model to evaluate transplacental passage of *Trypanosoma cruzi*,” *American Journal of Obstetrics and Gynecology*, vol. 192, no. 2, pp. 586–591, 2005.
 - [46] S. Drewlo, D. Baczyk, C. Dunk, and J. Kingdom, “Fusion assays and models for the trophoblast,” *Methods in Molecular Biology*, vol. 475, pp. 363–382, 2008.
 - [47] F. Frank, M. J. Sartori, C. Asteggiano, S. Lin, S. P. De Fabro, and R. E. Fretes, “The effect of placental subfractions on *Trypanosoma cruzi*,” *Experimental and Molecular Pathology*, vol. 69, no. 2, pp. 144–151, 2000.
 - [48] P. Libby, R. O. Bonow, D. L. Mann, and D. P. Zipes, *Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine*, Elsevier, New York, NY, USA, 8th edition, 2008.
 - [49] J. Duaso, G. Rojo, F. Jaña et al., “*Trypanosoma cruzi* induces apoptosis in ex vivo infected human chorionic villi,” *Placenta*, vol. 32, no. 5, pp. 356–361, 2011.
 - [50] T. C. Cardenas, C. A. Johnson, S. Pratap et al., “Regulation of the extracellular matrix interactome by *Trypanosoma cruzi*,” *Open Parasitology Journal*, vol. 4, pp. 72–76, 2010.
 - [51] A. P. M. P. Marino, A. A. Silva, R. T. Pinho, and J. Lannes-Vieira, “*Trypanosoma cruzi* infection: a continuous invader-host cell cross talk with participation of extracellular matrix and adhesion and chemoattractant molecules,” *Brazilian Journal of Medical and Biological Research*, vol. 36, no. 8, pp. 1121–1133, 2003.
 - [52] R. O. Calderón and S. P. de Fabro, “*Trypanosoma cruzi*: fusogenic ability of membranes from cultured epimastigotes in interaction with human syncytiotrophoblast,” *Experimental Parasitology*, vol. 56, no. 2, pp. 169–179, 1983.
 - [53] M. J. Sartori, S. Lin, R. E. Fretes, L. Ruiz Moreno, L. Goldemberg, and S. P. de Fabro, “Alkaline phosphatase activity in plasma of pregnant chagasic patients,” *Revista de la Facultad de Ciencias Médicas*, vol. 55, no. 1-2, pp. 5–8, 1997.
 - [54] M. J. Sartori, S. Lin, F. M. Frank, E. L. Malchiodi, and S. P. De Fabro, “Role of placental alkaline phosphatase in the interaction between human placental trophoblast and *Trypanosoma cruzi*,” *Experimental and Molecular Pathology*, vol. 72, no. 1, pp. 84–90, 2002.
 - [55] C. Diaz-Luján, M. F. Triquell, A. Schijman, P. Paglini, and R. E. Fretes, “Differential susceptibility of isolated human trophoblasts to infection by *Trypanosoma cruzi*,” *Placenta*, vol. 33, no. 4, pp. 264–270, 2012.



**The Scientific
World Journal**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014



**Gastroenterology
Research and Practice**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014



**MEDIATORS
of
INFLAMMATION**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014



**Journal of
Diabetes Research**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014



Disease Markers

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014



**Journal of
Immunology Research**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014



PPAR Research

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014



Hindawi

Submit your manuscripts at
<http://www.hindawi.com>



**International Journal of
Endocrinology**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014




**BioMed
Research International**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014




**Journal of
Ophthalmology**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014




**Stem Cells
International**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014



eCAM
Evidence-Based
Complementary and
Alternative Medicine

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014



**Journal of
Obesity**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014



**Journal of
Oncology**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014



**Computational and
Mathematical Methods
in Medicine**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014



**Behavioural
Neurology**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014



**Parkinson's
Disease**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014



**AIDS
Research and Treatment**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014



**Oxidative Medicine
and
Cellular Longevity**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014